Literature DB >> 2339105

Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology.

J B van Bree1, S Tio, A G de Boer, M Danhof, J C Verhoef, D D Breimer.   

Abstract

The pharmacokinetic characteristics of desglycinamide-arginine vasopressin (DGAVP) with respect to its transport across the blood-brain barrier (BBB) were studied with the use of serial CSF sampling in an individual animal and the unit impulse response methodology. Transport rate is determined as BBB clearance, the volume of plasma per unit time cleared of the peptide by BBB transport, and the extent of transport as the percentage of the administered dose transported into the central nervous system. Plasma kinetics of DGAVP were shown to be linear within the dose range studied (50-150 micrograms), plasma mean residence time (MRT) being 18 +/- 4 min (mean +/- SE; n = 9). Elimination of DGAVP from CSF after icv administration was linear, with an MRT of 10 +/- 1 min (n = 9). After iv administration of 100 micrograms DGAVP, CSF concentrations were detectable for 90 min. Transport from plasma to the central nervous system was linear. The BBB transport clearance value was 1.0 +/- 0.3 microliters/min, and 0.026 +/- 0.007% of the administered dose was transported into the central nervous system. Results demonstrate that, within the concentration range studied, DGAVP is transported across the BBB by passive diffusion, although to a very low extent.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2339105     DOI: 10.1023/a:1015838532048

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  36 in total

1.  Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain.

Authors:  B V Zlokovic; V T Susic; H Davson; D J Begley; R M Jankov; D M Mitrovic; M N Lipovac
Journal:  Peptides       Date:  1989 Mar-Apr       Impact factor: 3.750

2.  Transport of vasopressin fragments across the blood-brain barrier: in vitro studies using monolayer cultures of bovine brain endothelial cells.

Authors:  J B van Bree; A G de Boer; J C Verhoef; M Danhof; D D Breimer
Journal:  J Pharmacol Exp Ther       Date:  1989-06       Impact factor: 4.030

3.  Time sequential prediction of ventricular-vascular interactions.

Authors:  T W Latson; W C Hunter; D Burkhoff; K Sagawa
Journal:  Am J Physiol       Date:  1986-12

4.  Blood-cerebrospinal fluid barrier to arginine-vasopressin, desmopressin and desglycinamide arginine-vasopressin in the dog.

Authors:  V T Ang; J S Jenkins
Journal:  J Endocrinol       Date:  1982-06       Impact factor: 4.286

5.  Evidence for selective inhibition of sympathetic outflow by oxotremorine.

Authors:  T Baum; F T Becker
Journal:  Eur J Pharmacol       Date:  1980-06-13       Impact factor: 4.432

6.  Blood-brain barrier transcytosis of insulin in developing rabbits.

Authors:  K R Duffy; W M Pardridge
Journal:  Brain Res       Date:  1987-09-08       Impact factor: 3.252

7.  Effects of desglycinamide9, (Arg8) vasopressin and vasopressin antiserum on the acquisition of intravenous cocaine self-administration in the rat.

Authors:  J de Vry; I Donselaar; J M van Ree
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

8.  Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability.

Authors:  W A Banks; A J Kastin
Journal:  Brain Res Bull       Date:  1985-09       Impact factor: 4.077

9.  Subcutaneous administration of behaviorally effective doses of arginine vasopressin change brain AVP content only in median eminence.

Authors:  S N Deyo; W J Shoemaker; A Ettenberg; F E Bloom; G F Koob
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

10.  Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration.

Authors:  N H Greig; T T Soncrant; K M Wozniak; S I Rapoport
Journal:  J Pharmacol Exp Ther       Date:  1988-05       Impact factor: 4.030

View more
  5 in total

Review 1.  Delivering peptides to the central nervous system: dilemmas and strategies.

Authors:  W A Banks; A J Kastin; C M Barrera
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

2.  Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue.

Authors:  K Morimoto; H Yamaguchi; Y Iwakura; M Miyazaki; E Nakatani; T Iwamoto; Y Ohashi; Y Nakai
Journal:  Pharm Res       Date:  1991-09       Impact factor: 4.200

Review 3.  Drug transport across the blood-brain barrier. III. Mechanisms and methods to improve drug delivery to the central nervous system.

Authors:  J B Van Bree; A G De Boer; M Danhof; D D Breimer
Journal:  Pharm World Sci       Date:  1993-02-19

4.  Effects of protease inhibitors on vasopressin transport across rat alveolar epithelial cell monolayers.

Authors:  H Yamahara; K Morimoto; V H Lee; K J Kim
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

5.  Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.

Authors:  Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-30       Impact factor: 2.745

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.